ASTRIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.54 USD | -0.09% |
|
-6.39% | +37.24% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 579M |
|---|---|---|---|---|---|
| Net income 2024 * | -79M | Net income 2025 * | -101M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.81
x | P/E ratio 2025 * |
-5.35
x | Employees | 59 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Astria Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -0.09% | ||
| 1 week | -6.39% | ||
| Current month | -25.12% | ||
| 1 month | -32.48% | ||
| 3 months | +48.24% | ||
| 6 months | +94.46% | ||
| Current year | +37.24% |
1 week
10.43
11.33
1 month
10.4316.90
Current year
6.5816.90
1 year
4.2616.90
3 years
2.3616.90
5 years
2.3653.40
10 years
2.361 017.60
| Managers | Title | Age | Since |
|---|---|---|---|
Jill Milne
FOU | Founder | 56 | 08-06-25 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 11-03-31 |
| Chief Tech/Sci/R&D Officer | - | 22-07-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 13-12-31 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 19-01-03 |
| Director/Board Member | 75 | 16-04-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% | ||
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 10.54 | -0.09% | 319,177 |
| 24-04-17 | 10.55 | -4.95% | 553,588 |
| 24-04-16 | 11.1 | +1.93% | 461,230 |
| 24-04-15 | 10.89 | +0.74% | 469,038 |
| 24-04-12 | 10.81 | -4.00% | 588,235 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.54
USD
Average target price
25.57
USD
Spread / Average Target
+142.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.24% | 579M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.19% | 21.66B | |
| -18.35% | 20.77B | |
| -7.87% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ATXS Stock
